Ferric carboxymaltose
- Product NameFerric carboxymaltose
- CAS9007-72-1
- CBNumberCB82717081
- MFC39H63FeO39
- MW1211.73912
- EINECS813-933-0
- MOL File9007-72-1.mol
Chemical Properties
InChIKey | CRTIFGUDJMSNSV-SJEGEKMXNA-K |
FDA UNII | 6897GXD6OE |
NCI Drug Dictionary | Injectafer |
Ferric carboxymaltose Chemical Properties,Usage,Production
Mechanism of action
Ferric carboxymaltose is a macromolecular ferric hydroxide carbohydrate complex, which allows for controlled delivery of iron within the cells of the reticuloendothelial system and subsequent delivery to the iron-binding proteins ferritin and transferrin, with minimal risk of release of large amounts of ionic iron in the serum. Intravenous administration of ferric carboxymaltose results in transient elevations in serum iron, serum ferritin and transferrin saturation, and, ultimately, in the correction of haemoglobin levels and replenishment of depleted iron stores.Clinical Use
Ferric carboxymaltose complex:Treatment of iron deficiency anaemia (when oral treatment is ineffective or contraindicated)Side effects
Ferric carboxymaltose was well tolerated, with most drug-related adverse events being mild to moderate in severity. Commonly reported drug-related adverse events included headache, dizziness, nausea, abdominal pain, constipation, diarrhoea, rash and injection site reactions.The incidence of drug-related adverse events in patients receiving intravenous ferric carboxymaltose was generally similar to that in patients receiving oral ferrous sulfate. In general, rash and local injection-site reactions were more common with ferric carboxymaltose, whereas gastrointestinal adverse events were more frequent with ferrous sulfate. In patients with chronic kidney disease undergoing haemodialysis, a lower proportion of ferric carboxymaltose than iron sucrose recipients experienced at least one drug-related adverse event.
Drug interactions
Potentially hazardous interactions with other drugs Dimercaprol: avoid concomitant use. Oral iron: reduced absorptionMetabolism
Most absorbed iron is bound to transferrin and transported to the bone marrow where it is incorporated into haemoglobin; the remainder is contained within the storage forms, ferritin or haemosiderin, or as myoglobin, with smaller amounts occurring in haem-containing enzymes or in plasma bound to transferrin. Only very small amounts of iron are excreted as the majority released after the destruction of the haemoglobin molecule is re-used.Preparation Products And Raw materials
Ferric carboxymaltose Supplier
Global(146)Suppliers
Supplier | Tel | Country | ProdList | Advantage | ||
---|---|---|---|---|---|---|
+86-0533-2091136 +8613864437655 |
ziboweibinmaoyi@163.com | China | 100 | 58 | ||
+8615151475053 | biopole@163.com | China | 37 | 58 | ||
+undefined86-15315557071 | sales02@sdzhonghuimaterial.com | China | 983 | 58 | ||
+86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21634 | 55 | ||
+undefined-21-51877795 | ivan@atkchemical.com | China | 32957 | 60 | ||
+86-023-6139-8061 +86-86-13650506873 |
sales@chemdad.com | China | 39894 | 58 | ||
+86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29811 | 58 | ||
+86-0519-85551759 +8613506123987 |
marketing1@neostarunited.com | China | 8838 | 58 | ||
0086 18039857276 18039857276 |
CHINA | 2783 | 58 | |||
+8617735180244 | mike_yan@xuanranglobal.com | CHINA | 4017 | 58 |
9007-72-1, Ferric carboxymaltoseRelated Search
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine